Another in-depth analysis of CD38 expression in a large cohort of T-ALL at diagnosis during chemotherapy and at relapse found that CD38 expression was positive in 97.9% of diagnosed patients, 88.7% patients with minimal residual disease (MRD) and 82.9% relapsed samples [82]. Here, CD38 is linked to acute lymphoblastic leukemia.